INLEXZO™ (gemcitabine intravesical system) @MultiVu
INLEXZO™ (gemcitabine intravesical system)  @MultiVu
Uploaded September 2025 | Updated November 2026, 3 hours ago
Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved INLEXZO™ (gemcitabine intravesical system), a new, potentially practice-changing approach for treating patients with certain types of bladder cancer, addressing the need for additional options following unsuccessful BCG therapy and for patients refusing or ineligible for bladder removal surgery (radical cystectomy).1 INLEXZO™, previously referred to as TAR-200, is indicated for the treatment of adult patients with Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors.

To view the multimedia release go to: multivu.com/johnson-and-johnson/9342851-en-johnson-and-johnson-fda-approval-inlexzo-gemcitabine-intravesical-system
INLEXZO™ (gemcitabine intravesical system)USTA Coaching Serve Your PassionCole Haan Comfortable™ Fall 2025 CampaignPolaris DAGOR Enters Call of Duty®: Modern Warfare® 4National Whataburger Honey Butter Chicken Biscuit DayResilience Remembered — The Salvation Army Commemorates 20 Years Since Hurricane KatrinaHershey’s - Happiness Is the Real GoldNature’s Own names John Cena ‘Breaducator’Achieving Carbon Neutrality in industries and transportation with ToshibaIntroducing the Early Educator of the Year AwardCartoon x Pro Club: Culture in every stitch 🔥A New Era for Hanuman Beverages: Expanding the Global Footprint Through World-Class Innovation
MultiVu |

INLEXZO™ (gemcitabine intravesical system)

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER